2021 World Conference on Lung Cancer (Posters)-FP12. Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers

FP12. Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers

Back to course

Video Transcription

Video Summary

The video presents a study on the outcomes of pembrolizumab and pembrolizumab combined with chemotherapy in treating advanced non-small cell lung cancer. The study analyzed blood-based biomarkers and identified patients who would benefit from the combined therapy. The groups were well-balanced except for age and performance status differences, but after controlling for these factors, no overall survival benefit was observed for adding chemotherapy to pembrolizumab. Certain blood biomarkers were found to be correlated with overall survival in patients treated with pembrolizumab alone, but not in patients treated with the combined therapy. A predictive score incorporating the DNLR biomarker showed that patients with high scores benefitted from the combined therapy. Treatment decisions should consider individual patient characteristics. Validation is needed.

Asset Subtitle

Liran Holtzman

Meta Tag

Speaker Liran Holtzman

Topic Predictive Tumor Based Assays/ Biomarkers/ Pathology

Keywords

pembrolizumab

chemotherapy

advanced non-small cell lung cancer

blood-based biomarkers

overall survival